Articles about Pharmaceuticals

Proposal, a win for RFK Jr’s Maha movement, is a ‘first step’ toward tackling plastic pollution, advocates sayThe Environmental Protection Agency (EPA) proposed on Thursday to include microplastics and pharmaceuticals on a list of contaminants in drinking water for the first time, a step that could lead to new limits on those substances for water utilities.Lee Zeldin, the EPA administrator, said they are responding to Americans who have worried about plastics and pharmaceuticals in their drinking water. The gesture also aims to hand a win to health secretary Robert FKennedy Jr’s Maha movement, which for months has pressured Zeldin to further crack down on environmental contaminants. Continue reading...

Health minister Mark Butler says federal government is ‘not negotiating’ when it comes to removing price protections on common medicationsGet our breaking news email, free app or daily news podcastAustralia will not cave in to pressure from pharmaceutical giants and the Trump administration by removing consumer price protections on common medications, the health minister, Mark Butler says.Donald Trump imposed a new 100% tariff on branded pharmaceuticals imported into the US overnight, Australian time, trying to force manufacturers to agree to drug-pricing deals or commit to making their products domestically. Continue reading...

• Eli Lilly announced the acquisition of Centessa Pharmaceuticals, a company developing treatments for excessive daytime sleepiness and neurological conditions, in a deal valued at up to $7.8 billion if certain conditions are met. • Centessa shares soared 44% on the news, while Lilly's stock rose 3.7%, helping offset broader market pressures from companies like McCormick. • The deal highlights Big Pharma's aggressive push into neuroscience amid rising demand for sleep disorder therapies, potentially boosting Lilly's pipeline.

• Express Scripts added CARDAMYST (etripamil) nasal spray to its commercial national formularies effective March 27, 2026, expanding access for commercially insured patients. • The FDA-approved self-administered spray converts acute paroxysmal supraventricular tachycardia (PSVT) episodes to sinus rhythm in adults. • This coverage decision makes the first-in-class treatment broadly affordable across the U.S., improving cardiovascular care options.

• Telix Pharmaceuticals resubmitted its New Drug Application to the U.S. FDA on March 16, 2026, for TLX101-Px (Pixclara®), a PET imaging agent targeting gliomas in adults and pediatrics. • The agent received Orphan Drug and Fast Track designations from the FDA due to its potential to address unmet needs in post-treatment glioma management, with 18F-FET PET already in international guidelines but no U.S.-approved equivalent. • Glioblastoma multiforme (GBM), the most common aggressive primary brain cancer, affects about 22,000 new U.S. cases yearly, with recurrence nearly universal and median survival of 12-15 months post-diagnosis.